USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
Czech investor the PPF Group and the affiliated biotech company SOTIO have announced a deal with Maverix Oncology, a private company with a proprietary pipeline of targeted, small molecule cancer chemo-immunotherapeutics. 15 October 2019
UK-based biotech firm Prokarium says it has received an investment of £4.59 million ($5.6 million) from the Wellcome Trust to fund two clinical trials of its lead program, Entervax, a bivalent vaccine against enteric fever. 9 October 2019
The growing stable of Flagship Pioneering now has another member, with this one purportedly the world’s first exoneural biology company. 8 October 2019
Icosavax has announced the launch of the company with a $51 million Series A financing, led by Qiming Venture Partners USA and joined by Adams Street Partners, Sanofi Ventures and NanoDimension, with continuing support from its seed investors. 4 October 2019
California, USA-based discovery start-up Tenaya Therapeutics today announced the successful completion of a $92 million Series B financing. 3 October 2019
A report from the UK BioIndustry Association (BIA) finds that investment in UK biotech companies is slowing, with a total of £869 million ($1 billion) being raised for the year up to 31 August. 2 October 2019
Health Sciences Acquisitions Corp and Immunovant Sciences, a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases and a member of Switzerland's Roivant family of companies, today announced that they have entered into a definitive share exchange agreement (SEA). 2 October 2019
Shares of clinical-stage US biotech Provention Bio rose 6% in pre-market trading in reaction to reiteration of its registration plan for its Breakthrough Therapy-designated teplizumab (PRV-031) for the prevention or delay of clinical type 1 diabetes in at-risk people 24 September 2019
A new commercial licensing agreement between Bayer and digital therapeutic specialist One Drop will give the German pharma major access to an integrated platform for tracking and managing health conditions. 17 September 2019
While there are several commonly-cited reasons for the present pre-eminence of the Cambridge-Boston biotech cluster, it's clear that the hub is greater than the sum of its parts. 16 September 2019
Howard Rowe, managing director and head of healthcare, Hayfin Capital Management, considers the impact of divestments necessitated by big companies' major acquisitions, in an Expert View piece. 5 September 2019
Investors in the Atlas Venture-backed immuno-oncology specialist Surface Oncology have had a rough time since the company went public in New York, early in 2018. 5 September 2019
UK biotech start-up Achilles Therapeutics says it has closed a £100 million ($120.6 million) Series B financing led by incoming US investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group. 3 September 2019
Canada-headquartered ESSA Pharma said on Tuesday that, further to its previously announced equity offering, it has closed a public offering of the firm’s equity securities in Canada and a concurrent private placement of equity securities in the USA for aggregate gross proceeds of $36 million. 28 August 2019
European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new 400 million-euro ($488 million) fund. This brings the total amount raised by Medicxi in the last three years to over $1 billion. 19 July 2019
The global advanced therapy medicinal product (ATMP) sector is growing rapidly, with more than 900 developers active in this space, sponsoring 1,060 clinical trials, including 93 Phase III studies. 18 July 2019
Denmark’s Sunstone Life Science Ventures has invested five million euros ($5.6 million) out of its Life Science Ventures Fund IV into Forendo Pharma, a Finnish clinical-stage drug development company focusing on novel treatments in women's health. 17 July 2019
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news